



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)
 Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24
 E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 31.03.2010

Particulars	(Rs. in lacs)			
	Quarter ended 31.03.2010 Unaudited	Quarter ended 31.03.2009 Unaudited	12 Months ended 31.03.2010 Unaudited	12 Months ended 31.03.2009 Audited
1(a) Net sales/Income from Operations	3957.77	3235.16	13959.35	13619.76
1(b) Other Operating Income				
Total	3957.77	3235.16	13959.35	13619.76
2 Expenditure				
a. (Inc.)/Dec. in Stock in trade and work in progress	-230.66	-401.28	-1041.37	787.24
b. Consumption of Raw Materials	2430.37	2086.41	7219.33	6338.40
c. Purchase of traded goods	20.01	133.91	1372.92	764.68
d. Employees Cost	600.41	485.53	2375.10	1969.07
e. Depreciation	50.01	27.49	199.89	124.98
f. Other Expenditure	652.31	529.32	2483.79	2214.67
g. Total	3522.45	2861.38	12609.66	12199.04
3 Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	435.32	373.78	1349.69	1420.72
4 Other Income	29.89	27.06	29.89	27.06
5 Profit before Int. & Exceptional Items (3+4)	465.21	400.84	1379.58	1447.78
6 Interest	84.34	114.06	340.08	457.93
7 Profit After Interest but before Exceptional items (5 - 6)	380.87	286.78	1039.50	989.85
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	380.87	286.78	1039.50	989.85
10 Tax expense	24.69	175.62	124.69	372.62
11 Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	356.18	111.16	914.81	617.23
12 Extraordinary Items (net of tax expense)				
13 Net Profit (+)/ Loss (-) for the period (11-12)	356.18	111.16	914.81	617.23
14 Paid up Eq. Sh. Cap. (Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
15 Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr. Earnings Per Share (EPS)				
a. Basic & diluted EPS before extraordinary items for the period.	1.36	0.42	3.49	2.36
b. Basic & diluted EPS after extraordinary items for the period.	1.36	0.42	3.49	2.36
17 Public shareholding :				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
18 Promoter and promoter group shareholding				
a. Pledged / Encumbered				
- Number of shares	-	-	-	-
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
b. Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%

Notes

- The Financial Results for the Quarter ended 31.3.2010 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-5-10
- No complaints were pending at the beginning/end of the quarter ended 31.3.2010. However 43 requests for change of address/ dividend revaluation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.



By Order of the Board
 for Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
 Managing Director

Place : New Delhi
 Date : 13.05.2010